|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 13, 2016 ) The latest market report published by Credence Research, Inc. “Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the irritable bowel syndrome with diarrhea (IBS-D) drugs market was valued at USD 289.3 Mn in 2015, and is expected to reach USD 1,115.06 Mn by 2022, expanding at a CAGR of 13.89% from 2016 to 2022.
Browse the full report Irritable Bowel Syndrome with Diarrhea (IBS-D) 2016–2022 report at http://www.credenceresearch.com/report/irritable-bowel-syndrome-ibs-with-Diarrhea-drugs-market
Market Insights
IBS affects between 10% to 20% individuals in the developed countries. Since the underlying cause of IBD remains unknown, the treatment market for the same is observed to be unvisited and is characterized by very few indicated drugs. By far, alosetron has been the only drug approved for IBS-D treatment. With the approval for eluxadoline (Viberzi) and rifaximin (Xifaxan), new avenues in the IBS-D treatment market have opened, giving hopes to the patients.
Both Viberzi and Xifaxan are determined to be safe, Viberzi may receive controlled substance label due to risk of potential abuse. Viberzi and other IBS-D drugs act on opioid receptors, thus it is a mu receptor antagonist and kappa receptor antagonist. On the other hand, Xifaxan is viewed as a curative regimen, since it acts by altering the bacterial flora in the guts.
For More Reports Related to This Category @ http://www.credenceresearch.com/industry/pharmaceuticals-market
Xifaxan has been reportedly prescribed off label for treating IBS-D. Its formal sanction will thus support the growth in demand for the drug in the forecast period. Xifaxan is prescribed for a 14 day, thrice a day dosage; with a further additional 1 week dosage if the need arises. However, its long term role in efficiently containing IBS-D is still questioned. Viberzi, on the other hand, easily fits the profile of everyday medication for chronic disease treatment, similar to diabetes and CVD treatments. Further safety and effective assessments on these drugs are lined up, which will clear the market status of the two drugs.
The market for Viberzi is expected to cross USD 6 Mn mark by 2022, whereas Xifaxan market is expected to progress at a CAGR of moderate 4.46% during 2016-2022. IBS-D affects over 15 million Americans, with no single drugs having a clear domination in the market. Loperamide, angidepressants, alosetron, bile acid binders and similar such drugs were the standard treatments in the past. Medical professionals have largely relied on trial and error approach for treating IBS-D patients.
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Blog: http://www.pdfdevices.com/xifaxan-and-viberzi-to-give-facelift-to-the-global-irritable-bowel-syndrome-with-diarrhea-drugs-market-reaching-usd-221-mn-by-2022/
Media Contact
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com
Crednce Research
Chris Smith
1-800-361-8290
sales@credenceresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
